Question . What other diabetes medication also reduces our risk of cancer ?
Answer . Metformin ( Glucophage )
A review in Medscape by Megan Brooks reviewed a study of women with ovarian cancer.
The the study team reported in Obstetrics and Gynecology, five-year progression-free survival rates were 51% in diabetic patients who used metformin, 8% in diabetic patients who did not use metformin, and 23% in nondiabetics (p=0.03).
Overall survival at five years was 63% in metformin users, 23% in non-metformin users and 37% in the nondiabetic group (p=0.03).
Obstet Gynecol 2012;119:61-
From Reuters Health Information
There are numerous studies reporting the anti - cancer effects of metformin in various type of cancers. Medscape has over 200 articles reporting on metformin and cancer. Almost all of the articles are reporting on the benefits of metformin in reducing the risk associated with cancer and some animal studies discussing the preventive aspects of metformin in cancer prevention. One article discussed the lack of effectiveness of metformin in reducing the mortality rate in women with advanced breast cancer . However they did not a trend in the reduction of distant metastasis in the women with diabetes taking metformin.
This is an exciting area of research that holds great promise in reducing all of the risk associated with cancer. I like the statement made by Dr. Romero in the Medscape article.
Dr. Iris L. Romero and colleagues from the University of Chicago, Illinois say their observations add to a "growing body of evidence" from epidemiologic and preclinical studies indicating that metformin has anti tumor effects.
Have fun, be Smart and be your doctors best assistant in your own health care
David Calder, MD
Can you name 2 diabetes medications that may be associated with increased risk of cancer ?
Reporting an error. A few days ago I reported a price reduction in Diabetes Office Visit App. for iPhones and iPads.the change did not occur due to my error . I have corrected the problem. the new price is now .99 cents.